What Genes Can Tell: A Closer Look at Vestibular Schwannoma.


Journal

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504

Informations de publication

Date de publication:
04 2020
Historique:
entrez: 17 3 2020
pubmed: 17 3 2020
medline: 15 4 2021
Statut: ppublish

Résumé

Comprehensive molecular profiling of radioresistant and cystic vestibular schwannoma (VS) subtypes. Our study utilized whole-exome sequencing (WES), RNA-sequencing (RNAseq), and correlated clinical data from 12 samples (2 samples of solid sporadic subtype, 8 with cystic changes, and 2 previously irradiated). Academic medical center. Patients diagnosed with VS who required surgical treatment. Inclusion: Cystic and radioresistant tumors matched to age and tumor volume, with solid sporadic VS samples as control; Exclusion: NF-2 patients. WES using custom probes for copy number analysis. A modified version of the Agilent Human Whole Exome sequencing hybrid capture system was used to process samples. Recurrent variants were identified and compared between groups. Leukocyte-derived DNA was utilized as internal control to reduce false-positives. Analysis of genetic landscape of VS subtypes (naive solid VS, cystic VS, and previously irradiated VS) by performing deep next-generation sequencing. WES data achieved a mean coverage of 202X and RNAseq generated an average of 74 million total reads. As a group, 25% of samples had 22q loss. Somatic analysis identified previously reported genes and multiple novel mutations across samples. Differential expression analysis of RNAseq data found significantly mutated genes such as COL6A3, CLMP, ART4, Lumican that were shared by both cystic VS and irradiated VS, but not seen in sporadic VS. Using WES we were able to demonstrate that cystic and irradiated samples are subtypes of VS with an increased mutation burden and a unique genetic fingerprint. We identified differences between the genomic and molecular profile of cystic VS and radioresistant VS. Our results help advance the understanding of the pathophysiology of these tumor subtypes and suggest possible molecular targets for novel treatment strategies.

Identifiants

pubmed: 32176142
doi: 10.1097/MAO.0000000000002580
pii: 00129492-202004000-00025
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

522-529

Références

Dunn IF, Bi WL, Mukundan S, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on the role of imaging in the diagnosis and management of patients with vestibular schwannomas. Neurosurgery 2018; 82:E32–E34.
Lin EP, Crane BT. The management and imaging of vestibular schwannomas. AJNR Am J Neuroradiol 2017; 38:2034–2043.
Younes E, Montava M, Bachelard-Serra M, Jaloux L, Salburgo F, Lavieille JP. Intracanalicular vestibular schwannomas: Initial clinical manifestation, imaging classification, and risk stratification for management proposal. Otol Neurotol 2017; 38:1345–1350.
Rosenberg SI. Natural history of acoustic neuromas. Laryngoscope 2000; 110:497–508.
Battaglia A, Mastrodimos B, Cueva R. Comparison of growth patterns of acoustic neuromas with and without radiosurgery. Otol Neurotol 2006; 27:705–712.
Yashar P, Zada G, Harris B, Giannotta SL. Extent of resection and early postoperative outcomes following removal of cystic vestibular schwannomas: Surgical experience over a decade and review of the literature. Neurosurg Focus 2012; 33:E13.
Tang IP, Freeman SR, Rutherford SA, King AT, Ramsden RT, Lloyd SK. Surgical outcomes in cystic vestibular schwannoma versus solid vestibular schwannoma. Otol Neurotol 2014; 35:1266–1270.
Boari N, Bailo M, Gagliardi F, et al. Gamma Knife radiosurgery for vestibular schwannoma: Clinical results at long-term follow-up in a series of 379 patients. J Neurosurg 2014; 121: (suppl): 123–142.
Coughlin AR, Willman TJ, Gubbels SP. Systematic review of hearing preservation after radiotherapy for vestibular schwannoma. Otol Neurotol 2018; 39:273–283.
Kim JH, Jung HH, Chang JH, Chang JW, Park YG, Chang WS. Predictive factors of unfavorable events after gamma knife radiosurgery for vestibular schwannoma. World Neurosurg 2017; 107:175–184.
Muzevic D, Legcevic J, Splavski B, Caye-Thomasen P. Stereotactic radiotherapy for vestibular schwannoma. Cochrane Database Syst Rev 2014; CD009897.
Yeung AH, Sughrue ME, Kane AJ, Tihan T, Cheung SW, Parsa AT. Radiobiology of vestibular schwannomas: Mechanisms of radioresistance and potential targets for therapeutic sensitization. Neurosurg Focus 2009; 27:E2.
Lee JD, Kwon TJ, Kim UK, Lee WS. Genetic and epigenetic alterations of the NF2 gene in sporadic vestibular schwannomas. PLoS One 2012; 7:e30418.
Agnihotri S, Jalali S, Wilson MR, et al. The genomic landscape of schwannoma. Nat Genet 2016; 48:1339–1348.
Carlson ML, Smadbeck JB, Link MJ, Klee EW, Vasmatzis G, Schimmenti LA. Next generation sequencing of sporadic vestibular schwannoma: Necessity of biallelic NF2 inactivation and implications of accessory non-NF2 variants. Otol Neurotol 2018; 39:e860–e871.
Chen H, Xue L, Wang H, Wang Z, Wu H. Differential NF2 gene status in sporadic vestibular schwannomas and its prognostic impact on tumour growth patterns. Sci Rep 2017; 7:5470.
Håvik AL, Bruland O, Myrseth E, et al. Genetic landscape of sporadic vestibular schwannoma. J Neurosurg 2018; 128:911–922.
Neff BA, Welling DB, Akhmametyeva E, Chang LS. The molecular biology of vestibular schwannomas: Dissecting the pathogenic process at the molecular level. Otol Neurotol 2006; 27:197–208.
Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25:1754–1760.
McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20:1297–1303.
Patro R, Mount SM, Kingsford C. Sailfish enables alignment-free isoform quantification from RNA-seq reads using lightweight algorithms. Nat Biotechnol 2014; 32:462–464.
Manojlovic Z, Christofferson A, Liang WS, et al. Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS Genet 2017; 13:e1007087.
Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155:945–959.
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214–218.
Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12:R41.
Aran D, Hu Z, Butte AJ. xCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 2017; 18:220.
Repana D, Nulsen J, Dressler L, et al. The Network of Cancer Genes (NCG): A comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens. Genome Biol 2019; 20:1.
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15:550.
Diaz-Gay M, Vila-Casadesus M, Franch-Exposito S, Hernandez-Illan E, Lozano JJ, Castellvi-Bel S. Mutational Signatures in Cancer (MuSiCa): A web application to implement mutational signatures analysis in cancer samples. BMC Bioinformatics 2018; 19:224.
Rosenberg NA, Pritchard JK, Weber JL, et al. Genetic structure of human populations. Science 2002; 298:2381–2385.
Moon KS, Jung S, Seo SK, et al. Cystic vestibular schwannomas: A possible role of matrix metalloproteinase-2 in cyst development and unfavorable surgical outcome. J Neurosurg 2007; 106:866–871.
Zhang Z, Wang Z, Sun L, et al. Mutation spectrum and differential gene expression in cystic and solid vestibular schwannoma. Genet Med 2014; 16:264–270.
Huang Y, Li G, Wang K, et al. Collagen type VI alpha 3 chain promotes epithelial-mesenchymal transition in bladder cancer cells via transforming growth factor beta (TGF-beta)/smad pathway. Med Sci Monit 2018; 24:5346–5354.
Liu W, Li L, Ye H, Tao H, He H. Role of COL6A3 in colorectal cancer. Oncol Rep 2018; 39:2527–2536.
Wang X, Zhou Q, Yu Z, et al. Cancer-associated fibroblast-derived Lumican promotes gastric cancer progression via the integrin beta1-FAK signaling pathway. Int J Cancer 2017; 141:998–1010.
El Hajj N, Dittrich M, Haaf T. Epigenetic dysregulation of protocadherins in human disease. Semin Cell Dev Biol 2017; 69:172–182.
Sun S, Wang Y, Wu Y, et al. Identification of COL1A1 as an invasionrelated gene in malignant astrocytoma. Int J Oncol 2018; 53:2542–2554.
Wang X, Asplund AC, Porwit A, et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008; 143:248–252.
Jankowski MP, McIlwrath SL, Jing X, et al. Sox11 transcription factor modulates peripheral nerve regeneration in adult mice. Brain Res 2009; 1256:43–54.
Huang J, Ji EH, Zhao X, et al. Sox11 promotes head and neck cancer progression via the regulation of SDCCAG8. J Exp Clin Cancer Res 2019; 38:138.
Sa JK, Lee IH, Hong SD, Kong DS, Nam DH. Genomic and transcriptomic characterization of skull base chordoma. Oncotarget 2017; 8:1321–1328.
Jayasena CS, Bronner ME. Rbms3 functions in craniofacial development by posttranscriptionally modulating TGF-beta signaling. J Cell Biol 2012; 199:453–466.
Li Y, Chen L, Nie CJ, et al. Downregulation of RBMS3 is associated with poor prognosis in esophageal squamous cell carcinoma. Cancer Res 2011; 71:6106–6115.
Nikitenko L, Boshoff C. Endothelial cells and cancer. Handb Exp Pharmacol: 2006; (176 pt 2) 307–34.

Auteurs

Ksenia A Aaron (KA)

Department of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Stanford.
Department of Otolaryngology-Head and Neck Surgery.

Zarko Manojlovic (Z)

Department of Translational Genomics.

Nathan Tu (N)

Department of Otolaryngology-Head and Neck Surgery.

Yili Xu (Y)

Department of Translational Genomics.

Yuxin Jin (Y)

Department of Translational Genomics.

Sharon Chang (S)

Department of Translational Genomics.

Eric Kwok (E)

Department of Translational Genomics.

Michelle Webb (M)

Department of Translational Genomics.

Kyle Hurth (K)

Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles.

Rick A Friedman (RA)

Department of Otolaryngology-Head and Neck Surgery.
Department of Otolaryngology-Head and Neck Surgery, University of California San Diego, San Diego, California.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH